Journal of Biotechnology & Biomaterials
Open Access

Abstract

Alzheimerâ��s disease (AD) is a progressive and irreversible brain illness which gradually abolishes oneâ��s cognitive skills and rational thinking. The two major hallmarks of AD are the extracellular deposition of the Amyloid-beta (A�²) fragments resulting in plaques and intracellular accumulation of neurofibrillary tangles of tau protein. LilrB2 is a recently discovered receptor for A�² and is responsible for the increased accumulation and reduced clearance of A�² from the brain. Therefore, LilrB2 inhibition can suppress the aggregation of A�² plaques. In this study we have computationally modeled the 3D-structure of four isoforms of LilrB2. Structures were later super-imposed to calculate their RMSD and individually docked with A�² to examine the most appropriate isoform for inhibition. Virtual screening of best isoform reports some potential compounds which can inhibit LilrB2. Studies are underway to validate the identified compounds in the animal model of AD.

Biography

Ruchi Jakhmola Mani is a PhD scholar and Faculty of Bioinformatics at Amity Institute of Biotechnology, Amity University, India. She has completed her Master’s degree in Bioinformatics from Panjab University, Chandigarh. She has six years of teaching experience with some peer-reviewed publications. At present, she is working with zebrafish model of Alzheimer’s disease.

Email: ruchijakhmola@gmail.com